<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455453</url>
  </required_header>
  <id_info>
    <org_study_id>201411005</org_study_id>
    <secondary_id>5R01CA195450-03</secondary_id>
    <nct_id>NCT02455453</nct_id>
  </id_info>
  <brief_title>Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography</brief_title>
  <official_title>Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the uptake of a radioactive tracer&#xD;
      21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (FFNP)&#xD;
      uptake, which binds to breast cancer progesterone receptors (PgRs) on a PET/CT scan before&#xD;
      and after administration of estradiol for one day (estrogen challenge) to determine if the&#xD;
      change in uptake is a predictor of response to endocrine therapy (ET) in patients with&#xD;
      hormone-sensitive estrogen receptor positive (ER+), human epidermal growth factor receptor&#xD;
      2-negative (HER2-) breast cancer. Estradiol is the most potent of the naturally occurring&#xD;
      estrogens, and can be administered to treat menopausal symptoms and also sometimes to treat&#xD;
      metastatic breast cancer. The investigators propose to study patients with biopsy-proven&#xD;
      newly diagnosed, locally advanced, metastatic, or recurrent breast cancer who are going to be&#xD;
      treated with endocrine therapy (ET) (tamoxifen,aromatase inhibitors or fulvestrant as&#xD;
      standard of care therapy.&#xD;
&#xD;
      Subjects will undergo a total of two FFNP-PET/CT scans; one before and a second one&#xD;
      immediately following the one day estradiol challenge before the start of standard of care&#xD;
      ET. The estradiol challenge will consist of administering a total of 6 mg of estradiol orally&#xD;
      (three doses of 2 mg each) given at approximately 8 hour intervals and over a 24 hour period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Actual">January 3, 2019</completion_date>
  <primary_completion_date type="Actual">January 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</measure>
    <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Secondary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</measure>
    <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heterogeneity of Tumor FFNP Uptake as Measured by Number of Participants With Heterogenous Response</measure>
    <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
    <description>As measured visually in known lesion by recording presence or absence of uptake with note of any changes between scans</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic FFNP-PET/CT Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FFNP</intervention_name>
    <arm_group_label>Diagnostic FFNP-PET/CT Scan</arm_group_label>
    <other_name>21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CTI/Siemens Biograph 40 PET/CT Scanner</intervention_name>
    <description>Will include (1) 18-FDG-PET/CT scan&#xD;
Will include (2) 18F-FFNP-PET/CT scans</description>
    <arm_group_label>Diagnostic FFNP-PET/CT Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <arm_group_label>Diagnostic FFNP-PET/CT Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FDG</intervention_name>
    <arm_group_label>Diagnostic FFNP-PET/CT Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be postmenopausal defined as meeting one or more of the following:&#xD;
&#xD;
               -  Age ≥ 60 years&#xD;
&#xD;
               -  Amenorrheic for at least 12 months&#xD;
&#xD;
               -  Surgically sterile- having undergone bilateral oophorectomy,&#xD;
&#xD;
               -  FSH level in postmenopausal range according to institutional standards (note&#xD;
                  follicle-stimulating hormone (FSH) laboratory testing must be ordered as standard&#xD;
                  of care to determine optimal treatment and should not be ordered simply to&#xD;
                  confirm eligibility to this study)&#xD;
&#xD;
               -  OR Pre-menopausal for whom standard estradiol treatment (ET) is planned with&#xD;
                  ovarian suppression (imaging on study should be completed prior to start of&#xD;
                  ovarian suppression)&#xD;
&#xD;
          -  Patient must have histological or cytological confirmed breast cancer and fall into&#xD;
             one of the following categories:&#xD;
&#xD;
               -  New diagnosis with plans for at least 6 months of neoadjuvant ET or any amount of&#xD;
                  neoadjuvant ET if surgery is planned as this will be used for response assessment&#xD;
                  .&#xD;
&#xD;
               -  Patients with newly diagnosed metastatic breast cancer or patient with known&#xD;
                  metastatic disease who has progressed while on therapy (no washout period is&#xD;
                  needed if the patient was treated with AIs or chemotherapy, but 2 months washout&#xD;
                  period is needed if the patient was treated with tamoxifen) who are going to be&#xD;
                  treated with ET.&#xD;
&#xD;
          -  Patient must have any one of the following types of breast cancer (primary or&#xD;
             metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.&#xD;
&#xD;
               -  ER+ is defined as Allred score of at least 4 and greater.&#xD;
&#xD;
               -  PgR+ is defined as Allred score of at least 4 and greater.&#xD;
&#xD;
               -  Immunohistochemistry (IHC) is the primary assay methodology for HER2. HER2-&#xD;
                  refers to HER2 of 0, 1+ by IHC or negative by fluorescence in situ hybridization&#xD;
                  (FISH)&#xD;
&#xD;
          -  Patient must have at least one measurable lesion according to RECIST 1.1 by&#xD;
             radiological evaluation (ultrasound, mammography, MRI, CT, PET) or physical&#xD;
             examination.&#xD;
&#xD;
               -  Patients with evaluable osseous metastasis that are lytic or mixed&#xD;
                  lytic-sclerotic are eligible.&#xD;
&#xD;
               -  Patients with hepatic lesions may be eligible provided the location of the lesion&#xD;
                  is peripheral or not too close to hepatic ducts. Decision on hepatic lesion&#xD;
                  eligibility will be made by the principal investigator or sub-investigator after&#xD;
                  careful review of all available imaging to ensure evaluation of the lesion will&#xD;
                  not be obscured by normal hepatobiliary excretion of 18F-FFNP.&#xD;
&#xD;
          -  Patient must be able to understand and willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
          -  Prior chemotherapy or endocrine therapy is allowed&#xD;
&#xD;
          -  The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0-2 or, based on the judgment of the treating medical oncologist, can tolerate&#xD;
             imaging and at least 6 months of ET&#xD;
&#xD;
          -  The patient should have a life expectancy of &gt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with other invasive malignancies, with the exception of non-melanoma skin&#xD;
             cancer or cervical carcinoma in-situ, who had (or have) any evidence of the other&#xD;
             cancer present within the last 5 years&#xD;
&#xD;
          -  Unable to tolerate up to 60 min of PET imaging per imaging session.&#xD;
&#xD;
          -  Patients with non-measurable non-evaluable lesions such as pleural effusion are not&#xD;
             eligible to participate.&#xD;
&#xD;
          -  Patients with vertebral lesions that, in the opinion of the Principal Investigator and&#xD;
             the treating medical oncologist, pose an imminent risk for cord compression.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farrokh Dehdashti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <results_first_submitted>December 16, 2019</results_first_submitted>
  <results_first_submitted_qc>January 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02455453/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02455453/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic FFNP-PET/CT Scan</title>
          <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic FFNP-PET/CT Scan</title>
          <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="46" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</title>
        <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
        <population>2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic FFNP-PET/CT Scan</title>
            <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</title>
          <population>2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
          <units>percent change in SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="-46.0" upper_limit="306.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Secondary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</title>
        <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
        <population>12 participants were not included in this outcome measure as they did not have a secondary tumor location and 2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic FFNP-PET/CT Scan</title>
            <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Secondary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV)</title>
          <population>12 participants were not included in this outcome measure as they did not have a secondary tumor location and 2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
          <units>percent change in SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="-48.0" upper_limit="306.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heterogeneity of Tumor FFNP Uptake as Measured by Number of Participants With Heterogenous Response</title>
        <description>As measured visually in known lesion by recording presence or absence of uptake with note of any changes between scans</description>
        <time_frame>Completion of second FFNP-PET/CT scan (up to 4 weeks)</time_frame>
        <population>2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic FFNP-PET/CT Scan</title>
            <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Heterogeneity of Tumor FFNP Uptake as Measured by Number of Participants With Heterogenous Response</title>
          <description>As measured visually in known lesion by recording presence or absence of uptake with note of any changes between scans</description>
          <population>2 participants were not included in this outcome measure as the liver background was too high in both participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For FFNP-PET/CT imagings, participants were contacted by phone or in person approximately 24 +/- 6 hours after the injection of 18FFNP to assess for adverse events as related to 18F-FFNP injection, or PET/CT imaging. Any adverse events that occurred within 24 hours of administration of 18F-FFNP or within 24 hours of the first dose of estradiol which are graded related or possibly related were reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic FFNP-PET/CT Scan</title>
          <description>(2) 18F-FFNP-PET/CT scans&#xD;
First one prior to estradiol challenge test&#xD;
Second one immediately following one day of estradiol challenge test&#xD;
(1) FDG-PET/CT scan at screening&#xD;
The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Shoulder/joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bug bite or welt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farrokh Dehdashti, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-1604</phone>
      <email>dehdashtif@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

